Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma

doi:10.3760/cma.j.cn371439-20200601-00034

Abstract

Abstract:

Glioma is a tumor with a high incidence of intracranial tumor. Because of its high degree of malignancy, strong invasiveness and high mortality, the current conventional treatment cannot achieve the desired therapeutic effect, which greatly affects the quality of life of patients. As a protein with the functions of anti-proliferation, anti-angiogenesis and anti-invasion, interferon is widely used in the treatment of all kinds of tumors in clinic. Many studies have shown that interferon plays an important role in the occurrence and development of gliomas. To explore the mechanism of interferon and its related signal pathway in the process of glioma invasion, and to study the new treatment of glioma is very necessary in clinical treatment.

Key words: Glioma, Invasion, Interferon

Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma[J]. Journal of International Oncology, 2021, 48(3): 172-175.

References 29

[1]	Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance[J]. Neurotherapeutics, 2017,14(2):284-297. DOI: 10.1007/s13311-017-0519-x. doi: 10.1007/s13311-017-0519-x pmid: 28281173
[2]	Abrams DA, Hanson JA, Brown JM, et al. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma[J]. J Clin Neurosci, 2015,22(1):35-39. DOI: 10.1016/j.jocn.2014.05.054. doi: 10.1016/j.jocn.2014.05.054 pmid: 25481268
[3]	Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-gamma at the crossroads of tumor immune surveillance or evasion[J]. Front Immunol, 2018,9:847. DOI: 10.3389/fimmu.2018.00847. doi: 10.3389/fimmu.2018.00847 pmid: 29780381
[4]	Yokota A, Hirai H, Sato R, et al. C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells[J]. Blood Adv, 2019,3(3):476-488. DOI: 10.1182/bloodadvances.2018020503. pmid: 30755436
[5]	Lohmann B, Le Rhun E, Silginer M, et al. nterferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02[J]. Oncol Lett, 2020,19(4):2649-2656. DOI: 10.3892/ol.2020.11362. doi: 10.3892/ol.2020.11362 pmid: 32218815
[6]	Medrano RFV, Hunger A, Mendonça SA, et al. Immunomodulatory and antitumor effects of type Ⅰ interferons and their application in cancer therapy[J]. Oncotarget, 2017,8(41):71249-71284. DOI: 10.18632/oncotarget.19531. doi: 10.18632/oncotarget.19531 pmid: 29050360
[7]	Swiatek-Machado K, Kaminska B. STAT signaling in glioma cells[J]. Adv Exp Med Biol, 2020,1202:203-222. DOI: 10.1007/978-3-030-30651-9_10. pmid: 32034715
[8]	Zhang Y, Liu Z. STAT1 in cancer: friend or foe?[J]. Discov Med, 2017,24(130):19-29. pmid: 28950072
[9]	Hua L, Wang G, Wang Z, et al. Activation of STAT1 by the FRK tyrosine kinase is associated with human glioma growth[J]. J Neurooncol, 2019,143(1):35-47. DOI: 10.1007/s11060-019-03143-w. doi: 10.1007/s11060-019-03143-w pmid: 30993511
[10]	Zhang Y, Jin G, Zhang J, et al. Overexpression of STAT1 suppresses angiogenesis under hypoxia by regulating VEGF A in human glioma cells[J]. Biomed Pharmacother, 2018,104:566-575. DOI: 10.1016/j.biopha.2018.05.079. doi: 10.1016/j.biopha.2018.05.079 pmid: 29800921
[11]	Arslan AD, Sassano A, Saleiro D, et al. Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma[J]. Oncogene, 2017,36(43):6006-6019. DOI: 10.1038/onc.2017.205. doi: 10.1038/onc.2017.205 pmid: 28671669
[12]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017,16(3):203-222. DOI: 10.1038/nrd.2016.246. doi: 10.1038/nrd.2016.246 pmid: 28209991
[13]	Chen J, Zhong Y, Li L. miR-124 and miR-203 synergistically inactivate EMT pathway via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC)[J]. J Transl Med, 2020,18(1):69. DOI: 10.1186/s12967-020-02242-x. doi: 10.1186/s12967-020-02242-x pmid: 32046742
[14]	Yang CH, Wang Y, Sims M, et al. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis[J]. Oncotarget, 2016,7(51):84017-84029. DOI: 10.18632/oncotarget.12401. doi: 10.18632/oncotarget.12401 pmid: 27705947
[15]	Zhou P, Jiang N, Zhang GX, et al. MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM.[J]. Acta Biochim Biophys Sin (Shanghai), 2016,48(8):696-703. DOI: 10.1093/abbs/gmw063. doi: 10.1093/abbs/gmw063
[16]	Yang CH, Wang Y, Sims M, et al. MicroRNA203a suppresses glioma tumorigenesis through an ATM-dependent interferon response pathway[J]. Oncotarget, 2017,8(68):112980-112991. DOI: 10.18632/oncotarget.22945. doi: 10.18632/oncotarget.22945 pmid: 29348882
[17]	Zhang J, Zhu ZQ, Li YX, et al. Tim-3 expression in glioma cells is associated with drug resistance[J]. J Cancer Res Ther, 2019,15(4):882-888. DOI: 10.4103/jcrt.JCRT_630_18. doi: 10.4103/jcrt.JCRT_630_18 pmid: 31436247
[18]	Liu Z, Han H, He X, et al. Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma[J]. Oncol Lett, 2016,11(3):1829-1834. DOI: 10.3892/ol.2016.4142. pmid: 26998085
[19]	Li X, Wang B, Gu L, et al. Tim-3 expression predicts the abnormal innate immune status and poor prognosis of glioma patients[J]. Clin Chim Acta, 2018,476:178-184. DOI: 10.1016/j.cca.2017.11.022. doi: 10.1016/j.cca.2017.11.022 pmid: 29174343
[20]	Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis[J]. FEBS Lett, 2018,592(12):2023-2031. DOI: 10.1002/1873-3468.13084. doi: 10.1002/1873-3468.13084 pmid: 29749098
[21]	Li G, Shen J, Cao J, et al. Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461[J]. J Exp Clin Cancer Res, 2018,37(1):78. DOI: 10.1186/s13046-018-0749-8. doi: 10.1186/s13046-018-0749-8 pmid: 29631594
[22]	George J, Banik NL, Ray SK. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines[J]. Int J Biochem Cell Biol, 2010,42(7):1164-1173. DOI: 10.1016/j.biocel.2010.04.002. doi: 10.1016/j.biocel.2010.04.002 pmid: 20394835
[23]	Sun G, Wang Y, Zhang J, et al. MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells[J]. J Cell Biochem, 2018,119(6):4540-4547. DOI: 10.1002/jcb.26591. pmid: 29323737
[24]	Sarma PP, Dutta D, Mirza Z, et al. [Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis][J]. Mol Biol (Mosk), 2017,51(2):334-341. DOI: 10.7868/S0026898417020185.
[25]	Shen D, Guo CC, Wang J, et al. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells[J]. Oncol Rep, 2015,34(5):2715-2721. DOI: 10.3892/or.2015.4232. doi: 10.3892/or.2015.4232 pmid: 26329778
[26]	Jiapaer S, Furuta T, Tanaka S, et al. Potential strategies overcoming the temozolomide resistance for glioblastoma[J]. Neurol Med Chir (Tokyo), 2018,58(10):405-421. DOI: 10.2176/nmc.ra.2018-0141. doi: 10.2176/nmc.ra.2018-0141
[27]	GuhaSarkar D, Neiswender J, Su Q, et al. Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model[J]. Mol Oncol, 2017,11(2):180-193. DOI: 10.1002/1878-0261.12020. doi: 10.1002/1878-0261.12020 pmid: 28098415
[28]	Pu W, Qiu J, Riggins GJ, et al. Matrix protease production, epithelial-to-mesenchymal transition marker expression and invasion of glioblastoma cells in response to osmotic or hydrostatic pressure[J]. Sci Rep, 2020,10(1):2634. DOI: 10.1038/s41598-020-59462-w. doi: 10.1038/s41598-020-59462-w pmid: 32060379
[29]	Wang H, Hou Y, Hu Y, et al. Enzyme-activatable interferon-poly(α-amino acid) conjugates for tumor microenvironment potentiation[J]. Biomacromolecules, 2019,20(8):3000-3008. DOI: 10.1021/acs.biomac.9b00560. pmid: 31310511